EpiVax, Inc.

EpiVax leads the industry in preclinical immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietary methods for T cell epitope identification and characterization, we employ a wide range of validated in silico and in vitro techniques. This comprehensive approach provides accurate and thorough insights into immunogenic potential, ensuring the efficacy and safety of our clients’ products. Headquartered in Providence, RI, EpiVax has been pushing the boundaries of computational immunology for over 25 years. Our expert team of scientists have developed broad analytical capabilities, empowering pharmaceutical developers to make well informed decisions. The goal is to aid in the development of next generation treatments by offering cutting-edge methods. We believe in the power of science to transform human and animal health worldwide. Our motto, “Fearless Science,” embodies our commitment to boldly advancing research, overcoming challenges, and driving progress in immunology. We invite you to join us in shaping a healthier future, where science knows no limits. For more information, visit www.epivax.com